ArticleInfectious disorders drug targets2022
Epidemiological Study of COVID-19 in Iran and the World: A Review Study.
Article in Infectious disorders drug targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Autoimmune-like hepatitis induced by drugs: Still many unanswered questions.World journal of hepatology · 2025Review
- Mental well-being and sleep quality among vocational college students in Sichuan, China during standardized COVID-19 management measures.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a new virus of the Coronaviridae family that is now spreading worldwide. Therefore, disseminating information about patients with the virus can help identify the virus, pathogenesis, and find treatments. The current study aimed to review the new coronavirus (COVID-19). To reach this aim, we searched keywords containing COVID-19, coronavirus, respiratory infection, epidemiology in Pub Med, Web of Science Direct, Scopus, Scientific Information Databases, and Google scholar. The results of our search led to the achievement of articles on the study of COVID-19. Based on the results of the study, COVID-19 is a global transmitter with rapid transmission power for which no specific drug has yet been found to treat it. The rapid spread of the COVID-19 virus, the relationship between disease severity and mortality with various factors, respiratory transmission, especially in the short distance, masks, hand washing, and physical distance observance as the most important way to prevent, diversify clinical symptoms and at the same time fever and cough as the most common clinical symptoms, treatment with non-specific antiviral drugs and treatment based on controlling clinical symptoms and strengthening immunity with known drugs, paying attention to children as asymptomatic carriers, and pretentious pregnancy in the event of COVID-19 are the most important findings of this study. The case fatality rate of COVID-19 has varied from 0.08% to 10.8% in the world, but fortunately, the number of patients who have recovered is very promising and more than 66 million people have recovered. There is still no effective drug or vaccine to prevent the disease and investigation in this field is ongoing. The only way to prevent and control the disease is adherence to the health protocols. Due to the need of the medical community to achieve the scientific results of this epidemic in Iran and other parts of the world, this article was written.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.